2-(4-(2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile | 1453083-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-(2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile
• 英文别名: 2-(4-(2-(4,4-Diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile；2-[4-[2-(4,4-diethyl-5-oxooxolan-2-yl)ethyl]piperazin-1-yl]benzonitrile
• CAS: 1453083-79-8
• 化学式: C₂₁H₂₉N₃O₂
• 分子量: 355.48
• InChiKey: LOQRLBJNTADHFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  56.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-(2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile 、 1-(4-氟苄基)哌嗪 、 1-(2-苯甲腈)哌嗪 生成 3,3-diethyl-5-(2-(4-(4-fluorobenzyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one
  参考文献：
  名称：

  NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE

  摘要：

  本发明的制药组合物包括具有疾病修饰作用的功能化内酯衍生物，用于治疗与5-羟色胺受体7活性失调相关的疾病。

  公开号：

  US20160016941A1
• 作为产物：
  描述：

  3,3-diethyl-5-(2-hydroxyethyl)dihydrofuran-2(3H)-one 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 72.0h， 生成 2-(4-(2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl)piperazin-1-yl)benzonitrile
  参考文献：
  名称：

  Homologation as a lead modification approach en route to a series of lactone-based muscarinic ligands

  摘要：

  Previous work identified the lactone ring as a useful scaffold for the design of muscarinic ligands and reported a lactone-based ligand with an IC50 of 340 nM. Using homologation as a lead modification approach, a new series of lactone-based compounds have been designed, synthesized, and screened in muscarinic binding assays. The approach provided a series of compounds with improved % inhibition values and identified the highest affinity lactone-based ligand reported to date. The results of these efforts and the structure-activity relationship for this series of lactones-based ligands are discussed.

  DOI：

  10.1007/s00044-013-0692-3

文献信息

• [EN] NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX LIANTS DES RÉCEPTEURS SIGMA 2 ET LEUR PROCÉDÉ D'UTILISATION
  申请人：TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：WO2016183150A1

  公开（公告）日：2016-11-17

  Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

  本发明的药物组合物包括具有疾病修饰作用的功能化内酯衍生物，在治疗与σ-2受体活性失调相关的疾病中发挥作用。
• [EN] NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR 7 DE LA 5-HYDROXYTRYPTAMINE ET LEUR PROCÉDÉ D'UTILISATION
  申请人：UNIV TEMPLE

  公开号：WO2014164756A1

  公开（公告）日：2014-10-09

  Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

  本发明的药物组合物包括具有疾病修饰作用的功能化内酯衍生物，在治疗与5-羟色胺受体7活性失调相关的疾病中发挥作用。
• Design, synthesis, and evaluation of novel, selective γ-butyrolactones sigma-2 ligands
  作者：Benjamin E. Blass、Rong Gao、Kevin M. Blattner、John C. Gordon、Douglas A. Pippin、Daniel J. Canney

  DOI：10.1007/s00044-021-02771-0

  日期：2021.9

  with a number of disease states such as schizophrenia, Alzheimer’s disease, neuropathic pain, traumatic brain injury, and cancer. We have recently identified a series of novel, functionalized γ-butyrolactones that are potent σ2 receptor ligands that are drug-like and identified a potential candidate (9z) for future in vivo study.

  在 sigma 受体首次公开近 40 年后，sigma-2 (σ2) 受体最近被鉴定为跨膜蛋白 97（TMEM97，也称为 MAC30（脑膜瘤相关蛋白）。这种大分子与许多疾病状态，如精神分裂症、阿尔茨海默病、神经性疼痛、创伤性脑损伤和癌症。我们最近确定了一系列新型的、功能化的 γ-丁内酯，它们是有效的 σ2 受体配体，类似于药物，并确定了一个潜在的候选者 (9z ) 用于未来的体内研究。
• 5-hydroxytryptamine receptor 7 activity modulators and their method of use
  申请人：TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US10239868B2

  公开（公告）日：2019-03-26

  Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

  本发明的药物组合物包括在治疗与 5-羟色胺受体 7 活性失调有关的疾病方面具有疾病调节作用的官能化内酯衍生物。
• NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE
  申请人：Temple University-Of The Commonwealth System of Higher Education

  公开号：US20180221365A1

  公开（公告）日：2018-08-09

  Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.